Trending

UCB

Amgen and UCB re-file Evenity for US approval

Amgen and UCB re-file Evenity for US approval

Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that

X

Amgen and UCB re-file Evenity for US approval

https://pharmaphorum.com/news/amgen-ucb-evenity-fda-filing/

FDA approves UCB’s Cimzia in plaque psoriasis

FDA approves UCB’s Cimzia in plaque psoriasis

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis

X

FDA approves UCB’s Cimzia in plaque psoriasis

https://pharmaphorum.com/news/fda-ucbs-cimzia-plaque-psoriasis/

UCB collaborates with Science 37 on virtual clinical trials

UCB collaborates with Science 37 on virtual clinical trials

UCB is changing the way it conducts some of its research studies, removing the need for patients to

X

UCB collaborates with Science 37 on virtual clinical trials

https://pharmaphorum.com/news/ucb-science-37-virtual-clinical-trials/

Can ‘design thinking’ revolutionise pharma’s culture?

Can ‘design thinking’ revolutionise pharma’s culture?

As part of pharmaphorum’s ‘eye-on-innovation’ series, Paul Tunnah speaks to UCB’s head of innovation, Gregory Miller, about how

X

Can ‘design thinking’ revolutionise pharma’s culture?

https://pharmaphorum.com/views-and-analysis/can-design-thinking-revolutionise-pharmas-culture/

FDA approves Pfizer’s Besponsa in aggressive blood cancer

FDA approves Pfizer’s Besponsa in aggressive blood cancer

Besponsa becomes first of its kind indicated for rare type of acute lymphoblastic leukaemia.

X

FDA approves Pfizer’s Besponsa in aggressive blood cancer

https://pharmaphorum.com/news/pfizer-besponsa-leukaemia/

UCB recruits Belgian wearables firm for epilepsy study

UCB recruits Belgian wearables firm for epilepsy study

Byteflies’ Sensor Dot will help monitor brain, heart and respiration activity.

X

UCB recruits Belgian wearables firm for epilepsy study

https://pharmaphorum.com/news/ucb-wearables-epilepsy/

FDA rejects Amgen/UCB osteoporosis drug

FDA rejects Amgen/UCB osteoporosis drug

The FDA has rejected Amgen and UCB’s Evenity (romosozumab) osteoporosis drug after a late-stage trial unexpectedly highlighted a

X

FDA rejects Amgen/UCB osteoporosis drug

https://pharmaphorum.com/news/fda-rejects-amgenucb-osteoporisis-drug/

Safety restrictions spell the end for Servier osteoporosis drug

Safety restrictions spell the end for Servier osteoporosis drug

Sales of Protelos hit by safety restrictions.

X

Safety restrictions spell the end for Servier osteoporosis drug

https://pharmaphorum.com/news/servier-end-production-osteoporosis-drug/

Amgen/UCB’s osteoporosis drug hit by cardio risk

Amgen/UCB’s osteoporosis drug hit by cardio risk

Competitor to Amgen’s Epogen also moves closer to market

X

Amgen/UCB’s osteoporosis drug hit by cardio risk

https://pharmaphorum.com/news/amgenucbs-osteoporosis-drug-hit-cardio-risk-data/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com